Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8041 to 8055 of 8981 results

  1. Venous leg ulcers - new treatments [ID394]

    Discontinued Reference number: GID-TAG370

    Technology appraisal guidance
    Discontinued

  2. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued Reference number: GID-TAG398

    Technology appraisal guidance
    Discontinued

  3. Faller's clinics for the assessment and prevention of falls [ID103]

    Discontinued Reference number: GID-TAG375

    Technology appraisal guidance
    Discontinued

  4. Intensity modulated radiotherapy for head and neck cancer [ID15]

    Discontinued Reference number: GID-TAG397

    Technology appraisal guidance
    Discontinued

  5. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued Reference number: GID-TAG378

    Technology appraisal guidance
    Discontinued

  6. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued Reference number: GID-TAG396

    Technology appraisal guidance
    Discontinued

  7. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued Reference number: GID-TAG399

    Technology appraisal guidance
    Discontinued

  8. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis [ID388]

    Discontinued Reference number: GID-TAG372

    Technology appraisal guidance
    Discontinued

  9. Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

    Discontinued Reference number: GID-TAG414

    Technology appraisal guidance
    Discontinued

  10. Multiple sclerosis - sativex [ID387]

    Discontinued Reference number: GID-TAG368

    Technology appraisal guidance
    Discontinued

  11. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued Reference number: GID-TAG393

    Technology appraisal guidance
    Discontinued

  12. Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]

    Discontinued Reference number: GID-TA10851

    Technology appraisal guidance
    Discontinued

  13. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    Discontinued Reference number: GID-HST10032

    Highly specialised technologies guidance
    Discontinued

  14. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued Reference number: GID-TA11421

    Technology appraisal guidance
    Discontinued

  15. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    Discontinued Reference number: GID-TA10958

    Technology appraisal guidance
    Discontinued